Skip to content
Open access

RACK1 maintains mouse hematopoietic stem cells by directly binding to and stabilizing LDB1

Aug 2026 · Cell Death & Disease · 0 citations

TL;DR

Single-cell RNA sequencing indicates that adulthood Rack1 deletion in type I interferon-I-responsive cells leads to aberrant lineage-geneset-scores of transcriptional HSCs and the emergence of stressed HSCs, and Mechanistically, RACK1 prevents HSC loss through maintaining the protein level of LDB1.

Abstract

A core complex with transcription factors (TFs) TAL1/TCF3/GATA2 and adaptors LMO2/LDB1 lies at the top of the hematopoietic transcriptional hierarchy. The mechanism(s) underlying the expression of these components remain elusive. Adaptor RACK1 interacts with multiple TFs and modulates their activation and/or stability. However, a role of RACK1 in the transcriptional control of hematopoietic stem cell (HSC) fates hasn’t been disclosed. Here, we report that RACK1 is expressed across various hematopoietic cell types. Adulthood Rack1 deletion in type I interferon- (IFN-I)-responsive cells leads to rapid and profound hematopoietic failure and HSC loss. HSC exhaustion upon adulthood Rack1 deletion results from cell-intrinsic defects with massive apoptosis. Single-cell RNA sequencing indicates that adulthood Rack1 deletion in IFN-I-responsive cells leads to aberrant lineage-geneset-scores of transcriptional HSCs and the emergence of stressed HSCs. Furthermore, prenatal deletion of Rack1 in hematopoietic cells results in reduced and defective HSCs in the fetal liver. Mechanistically, RACK1 prevents HSC loss through maintaining the protein level of LDB1. The direct interaction between RACK1 and LDB1 suppressing its ubiquitination and subsequent degradation, thereby stabilizes LDB1. Therefore, RACK1 maintains adult and fetal mouse HSCs through, at least partially, directly binding to and stabilizing LDB1.

Read PDF

Similar papers

Open access Jul 2026

Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry.

It is reported that an unappreciated RNA-binding protein, Rbm5, selectively promotes murine leukemogenesis, maintains LSC self-renewal in vivo, and is dispensable for normal hematopoiesis.

Mengli Zhang, Shaela Fields, Qiong Zhang et al. · 0 citations
Jul 2026

Prdm15 deficiency perturbs hematopoietic stem and progenitor cell homeostasis.

It is reported that Prdm15 deficiency in HSPCs induces the accumulation of immature hematopoietic stem cells in mice, establishing PRDM15 as a critical epigenetic regulator of HSPCs, offering valuable insights into the molecular mechanisms underlying hematopoietic homeostasis.

Qi-Wen Dong, Wei-Wei Xiao, Junsong Huang et al. · 0 citations
Open access Aug 2026

TAL1 is indispensable in ETV2-primed human endothelial cell fate determination

It is demonstrated that ETV2 drives the rapid forward programming of human pluripotent stem cells (hPSCs) into endothelial cells (ECs) by direct remodeling of endothelial-specific enhancers and is established as a master gatekeeper of human EC specification.

Yun Zhao, Mengze Sun, Zi-Xuan Hong et al. · 0 citations
Aug 2026

Locus-specific transposable element expression drives human hematopoietic stem cell disease pathophysiology

This study provides direct evidence that VEXAS-specific TE govern HSC clonal dominance, thereby uncovering a regulatory axis underlying HSC biology and disease mechanisms, opening a therapeutic strategy directed towards the repetitive genome.

A. Varesi, Sontago Dong, Chiara Gaddoni et al. · 0 citations

can modulate TAL1 transcriptional activity through interaction with LMO2

Initial evidence for a novel role of FOXP3 as a tumor suppressor in T-ALL through modulation of TAL1 transcriptional activity is provided through modulation of TAL1 transcriptional activity.

V. Fleskens, M. Mokry, A. M. van der Leun et al. · 0 citations
Open access Jul 2026

Targeting the NuRD Component, CHD4, Impairs Foxp3+ Treg Cell Production and Function and Promotes Anti-Tumor Immunity

CHD4 is identified as a critical epigenetic regulator of Treg lineage stability and pharmacological targeting of the CHD4/NuRD axis is established as a promising strategy to selectively disrupt tumor-associated Tregs and enhance antitumor immunity.

Yan Xiong, Li-Qing Wang, Martina Minisini et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.